A0774012
Alisertib (MLN8237) , ≥98% , 1028486-01-2
CAS NO.：1028486-01-2
Empirical Formula: C27H20ClFN4O4
Molecular Weight: 518.92
MDL number: MFCD16621243
EINECS: 1592732-453-0
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB460.80 | In Stock |
|
| 25MG | RMB1599.20 | In Stock |
|
| 100MG | RMB4388.80 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Boiling point: | 729.1±70.0 °C(Predicted) |
| Density | 1.43±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | Soluble in DMSO (up to 5 mg/ml) |
| form | solid |
| pka | 4.07±0.10(Predicted) |
| color | Off-white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Description and Uses
Alisertib (MLN8237, 1028486-01-2) is a highly selective and potent (IC50?= 1 nM) cell permeable inhibitor of Aurora A with off-target binding at GABAA?(IC50?= 490 nM).1?It disrupts the Aurora A-Myc complex leading to Myc degradation2?in Myc amplified neuroblastomas3?and p53-mutant human hepatocellular carcinoma cell4. Alisertib has been found to induce apoptosis and autophagy in breast cancer5?and melanoma6?cells?via?suppression of activation of the p38 MAPK pathway.
An Aurora kinase inhibitor, used to treat patients with advanced solid tumors.
Safety
| Signal word | Warning |
| Hazard statements | H320 |
| Precautionary statements | P264-P305+P351+P338-P337+P313 |
